Innovations in development for the biosimilar industry
03.11.55: Born in Offenbach, Germany 1974: High school diploma (Abitur) 1974-1975: Army service, Germany (15 months) 1977-1981: Student of biology, J.W. Goethe Univ. Frankfurt 1979-1982: Assistant at the faculty of biol…more ›
Dr. Carsten Brockmeyer is the owner and Managing Director of Brockmeyer Biopharma GmbH (www.brockmeyer-biopharma.com), a consulting firm providing strategic and operational support for novel and biosimilar biopharmaceutical development. Dr. Brockmeyer is a pioneer in th…more ›
Crawford co–founded Eden Biodesign in 2000 and prior to this he was Director of Product Development responsible for developing and manufacturing the biotech product pipeline at Celltech–Medeva. Among his achievements Crawford managed and led a successful pan–European su…more ›
As Vice President of Global Bioanalytical Services, Dr. Farmen leads one of the preeminent bioanalytical groups in the industry. In this role he is responsible for the bioanalytical groups in Lincoln, NE USA and Zurich, Switzerland. These groups offer exceptional expert…more ›
Dr. Stanley Hong is currently a Senior Vice President of Celltrion, Inc. in charge of R&D including biosimilar development. He has many experience in development of biopharmaceutical area as well as industrial enzymes. Dr. Hong joined Celltrion from the begining(20…more ›
The Leading scientific event for biosimilar drug development
Biosimilar Drug Development World provides you with the strategy and science to take biosimilars from bench to market. Come and learn:
- Biosimilar product development, CMC and comparative analysis
- Considerations for biosimilar manufacture, process development, scale-up and validation
- Non clinical studies for biosimilars
- Best practice in clinical trials design and execution
- The use of immunogenicity tools and techniques in development and the clinic
- Proven strategies in biosimilar pharmacovigilance and risk management
- Global regulatory requirements, the resulting impact on drug development, manufacture & clinical trials
Sponsors
The focus for Biosimilar Drug Development World Europe 2012
- Scientific foundations behind the development of biosimilars from the bench to market
- Biosimilar clinical trial requirements, challenges and opportunities
- Manufacturing process development and scale-up
- Biosimilar immunogenicity
- Global regulatory review and analysis
- Industry of tomorrow: How could the regulatory setting alter to improve access
Hear from: Sandoz International GmbH, Lupin Limited, Samsung, Sandoz Biopharmaceuticals, Wockhardt and many more!
Who should attend
- Formulation
- Development
- Reg Affairs
- Clinical Trials
- Pharmacovigilance
- Preclinical Dev
- Toxicology
- Manufacturing
- Bioequivalence
- CMC
Who should sponsor
- Full Service CRO
- Niche CRO
- Management Consultant
- Contract Manufacturing Organisation
- Clinical/Non Clinical IT Solutions
- Law Firms
There are limited sponsorship opportunities available
Generic Medicines Europe 2012
Biosimilar Drug Development Europe 2012 is co-located with the long running event Generic Medicines World Europe 2012. Register for this conference and get access to the sessions at World Generic Medicines Congress Europe as well!
Limited opportunities to speak at the conference exist for leading solution providers
